



## YOU ARE INVITED TO JOIN US FOR A CONTEMPORARY AND CLINICALLY RELEVANT EDUCATIONAL ACTIVITY.

This interactive and evidence-based program was developed by leading Canadian experts to address the importance of strict management of low density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease as well as provide a timely review of the results of recently completed clinical trials and their applicability to routine clinical practice.

### Join us for a group learning session

**Date:**

**Location:**

**Program Start Time:**

**Program End Time:**

\*Meal to follow the presentation

**Speaker (s):**

**RSVP:**

### AGENDA

The following modules will be presented:

- ☐ **New Horizons in Dyslipidemia Management in Primary Care**
- ☐ **Case 1:** - Diabetes & Cardiovascular Disease
- ☐ **Case 2:** - LDL-C: How Low Do You Go?
- ☐ **Case 3:** - ASCVD with Multiple CV Risk Factors
- ☐ **Case 4:** - Familial Hypercholesterolemia

### LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

- Discuss the role of LDL-C lowering in cardiovascular risk reduction with emphasis on the results of recently completed clinical trials
- Evaluate recommendations for lipid lowering agents beyond or in addition to statin therapy for patients with atherosclerotic cardiovascular disease
- Explain the mechanism of action of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and apply the latest clinical data to patient management strategies
- Apply best guideline practice recommendations into routine clinical practice based on specific patient characteristics

This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College's

This program has received an educational grant and in-kind support from Amgen Canada

